{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:20:52Z","timestamp":1760548852449},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s00415-009-5245-9","type":"journal-article","created":{"date-parts":[[2009,8,25]],"date-time":"2009-08-25T21:56:45Z","timestamp":1251237405000},"page":"299-305","source":"Crossref","is-referenced-by-count":9,"title":["Management of non-motor complications in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"256","author":[{"given":"Ken-ichi","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,27]]},"reference":[{"key":"5245_CR1","first-page":"430","volume":"42","author":"Ad Hoc Committee on the Guidelines for the Treatment of Parkinson\u2019s Disease. Japanese Neurological Society","year":"2002","unstructured":"Ad Hoc Committee on the Guidelines for the Treatment of Parkinson\u2019s Disease. Japanese Neurological Society (2002) Guidelines for the treatment of Parkinson\u2019s disease. Clin Neurol 42:430\u2013494","journal-title":"Clin Neurol"},{"key":"5245_CR2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","volume":"253","author":"P Barone","year":"2006","unstructured":"Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B, The Depression\/Parkinson Italian Study Group (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson\u2019s disease: a national multicenter parallel-group randomized study. J Neurol 253:601\u2013607","journal-title":"J Neurol"},{"key":"5245_CR3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00003495-197816040-00001","volume":"16","author":"RN Brogden","year":"1978","unstructured":"Brogden RN, Heel RC, Speight TM, Avery GS (1978) Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 16:273\u2013301","journal-title":"Drugs"},{"key":"5245_CR4","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.bjp.0702673","volume":"127","author":"MC Coldwell","year":"1999","unstructured":"Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN (1999) Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2 (long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127:1696\u20131702","journal-title":"Br J Pharmacol"},{"key":"5245_CR5","first-page":"313","volume":"59","author":"N Doi","year":"2007","unstructured":"Doi N, Sameshima T, Suwa H, Mera H, Nagao T, Yokochi M, Nakamura M, Isse K (2007) Electroconvulsive therapy for neurological disorders. Brain Nerve 59:313\u2013320","journal-title":"Brain Nerve"},{"key":"5245_CR6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","volume":"19","author":"AH Evans","year":"2004","unstructured":"Evans AH, Katzenschlager R, Paviour D, O\u2019Sullivan JD, Appel S, Lawrence AD, Lee AJ (2004) Punding in Parkinson\u2019s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397\u2013405","journal-title":"Mov Disord"},{"key":"5245_CR7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G Fenelon","year":"2000","unstructured":"Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson\u2019s disease. Prevalence, phenomenology and risk factors. Brain 123:733\u2013745","journal-title":"Brain"},{"key":"5245_CR8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1017\/S1092852900013778","volume":"13","author":"JM Ferrara","year":"2008","unstructured":"Ferrara JM, Stacy M (2008) Impulse\u2013control disorders in Parkinson\u2019s disease. CNS Spectra 13:690\u2013698","journal-title":"CNS Spectra"},{"key":"5245_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2006.08.007","volume":"17","author":"H Frieling","year":"2007","unstructured":"Frieling H, Hillemacher T, Ziegenbein M, Neund\u00f6rfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson\u2019s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165\u2013171","journal-title":"Eur Neuropsychopharmacol"},{"key":"5245_CR10","first-page":"1067","volume":"32","author":"K Fujimoto","year":"2004","unstructured":"Fujimoto K (2004) Patient selection in stereotaxic neurosurgery for Parkinson\u2019s disease: a guide to stereotactic brain operations. Neurol Surg 32:1067\u20131075","journal-title":"Neurol Surg"},{"key":"5245_CR11","first-page":"1039","volume":"60","author":"K Fujimoto","year":"2008","unstructured":"Fujimoto K (2008) Pathological gambling and Parkinson disease. Brain Nerve 60:1039\u20131046","journal-title":"Brain Nerve"},{"key":"5245_CR12","first-page":"274","volume":"53","author":"K Fujimoto","year":"2000","unstructured":"Fujimoto K, Sayama S, Shizuma N, Ikeguchi K, Nakano I (2000) Mianserin therapy for psychosis in parkinsonism. Neurol Med 53:274\u2013281","journal-title":"Neurol Med"},{"key":"5245_CR13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","volume":"68","author":"G Giovannoni","year":"2000","unstructured":"Giovannoni G, O\u2019Sullivan JD, Turner K, Manson AJ, Lees AJL (2000) Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiat 68:423\u2013428","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"5245_CR14","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"CG Goetz","year":"1993","unstructured":"Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson\u2019s disease. Neurology 43:2227\u20132229","journal-title":"Neurology"},{"key":"5245_CR15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(03)00555-6","volume":"2","author":"DS Goldstein","year":"2003","unstructured":"Goldstein DS (2003) Dysautonomia in Parkinson\u2019s disease: neurocardiological abnormalities. Lancet Neurol 2:669\u2013676","journal-title":"Lancet Neurol"},{"key":"5245_CR16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF02190411","volume":"244","author":"K Ikeguchi","year":"1995","unstructured":"Ikeguchi K, Kuroda A (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci 244:320\u2013324","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"5245_CR17","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1001\/jama.293.7.783","volume":"293","author":"BM Kuehn","year":"2005","unstructured":"Kuehn BM (2005) FDA warns antipsychotic drugs may be risky for elderly. JAMA 293:2462","journal-title":"JAMA"},{"key":"5245_CR18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jns.2006.05.024","volume":"248","author":"MR Lemke","year":"2006","unstructured":"Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson\u2019s disease. J Neurol Sci 248:266\u2013270","journal-title":"J Neurol Sci"},{"key":"5245_CR19","first-page":"295","volume-title":"Parkinson\u2019s disease","author":"CJ Mathias","year":"2005","unstructured":"Mathias CJ (2005) Cardiovascular autonomic dysfunction in Parkinson\u2019s disease and parkinsonian syndromes. In: Ebadi M, Pfeiffer RF (eds) Parkinson\u2019s disease. CRC Press LLC, New York, pp 295\u2013317"},{"key":"5245_CR20","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","volume":"20","author":"WG Ondo","year":"2005","unstructured":"Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease. Mov Disord 20:958\u2013963","journal-title":"Mov Disord"},{"key":"5245_CR21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","volume":"22","author":"JM Rabey","year":"2007","unstructured":"Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3\u00a0months\u2019 duration. Mov Disord 22:313\u2013318","journal-title":"Mov Disord"},{"key":"5245_CR22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"B Ravina","year":"2007","unstructured":"Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C (2007) Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061\u20131068","journal-title":"Mov Disord"},{"key":"5245_CR23","volume-title":"The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging","author":"Task force on ECT","year":"2001","unstructured":"Task force on ECT (2001) The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging, 2nd edn. American Psychiatric Association, Washington","edition":"2"},{"key":"5245_CR24","first-page":"130","volume":"96","author":"V Voon","year":"2005","unstructured":"Voon V, Moro E, Saint-Cyr JA, Lozano AM, Lang AE (2005) Psychiatric symptoms following surgery for Parkinson\u2019s disease with an emphasis on subthalamic stimulation. Adv Neurol 96:130\u2013147","journal-title":"Adv Neurol"},{"key":"5245_CR25","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1176\/appi.ajp.2007.07040715","volume":"164","author":"D Weintraub","year":"2007","unstructured":"Weintraub D, Hurtig HI (2007) Presentation and management of psychosis in Parkinson\u2019s disease and dementia with Lewy bodies. Am J Psychiatry 164:1491\u20131498","journal-title":"Am J Psychiatry"},{"issue":"suppl 3","key":"5245_CR26","doi-asserted-by":"crossref","first-page":"III\/22","DOI":"10.1007\/PL00007822","volume":"248","author":"ECh Wolters","year":"2001","unstructured":"Wolters ECh (2001) Intrinsic and extrinsic psychosis in Parkinson\u2019s disease. J Neurol 248(suppl 3):III\/22\u2013III\/27","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-5245-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-009-5245-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-5245-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:12:51Z","timestamp":1559056371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-009-5245-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":26,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["5245"],"URL":"https:\/\/doi.org\/10.1007\/s00415-009-5245-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}